Skip to main content

Generics

  • JAMA: Director of tobacco research suggests most benefits outweigh risks when considering cessation

    BOSTON — Smokers who have been unsuccessful to date in trying to kick the nicotine habit may be able to stop smoking by combining two smoking cessation approaches, according to a report published in the Oct. 17 issue of JAMA.  

  • FDA gives tentative approval to Cipla combo pill for HIV

    SILVER SPRING, Md. — The Food and Drug Administration has given tentative approval to a new drug for HIV made by an Indian company.

    FDA records show that the agency gave tentative approval tablets and oral suspension that combine lamivudine, nevirapine and zidovudine in the 30-mg/50-mg/60-mg strength.

  • Study: Regular blood glucose monitoring increases medication adherence

    MILPITAS, Calif. — Blood glucose monitoring is associated with reduced A1C levels and greater adherence to medication in Type 2 diabetes patients who do not take insulin, according to a study published in the September issue of Diabetes Technology & Therapeutics.

  • HDMA Factbook: 2011 health product sales reach $294 billion

    ARLINGTON, Va. — Healthcare product sales through the nation’s primary healthcare distributors hit a record high of $294 billion in 2011, according to the 2012-2013 HDMA Factbook released Friday. Specifically, pharmaceutical products moved by distributors represent approximately 90% of sales in the United States.

  • CDC study finds drops in cholesterol levels since 1988

    NEW YORK — An uptick in the use of cholesterol drugs since the late 1980s and changes in Americans' diets may account for a fall in cholesterol levels, according to a new study by the Centers for Disease Control and Prevention.

  • FDA approves generic Lupin contraceptive

    MUMBAI, India — The Food and Drug Administration has approved a generic contraceptive made by Indian drug maker Lupin, the company said Thursday.

    Lupin announced the approval of Kurvelo (levonorgestrel and ethinyl estradiol) tablets in the 0.15 mg/0.03 mg strength.

    The drug is a generic version of Teva's branded Nordette. Nordette had sales of about $59 million during the 12-month period ended in June, according to IMS Health.

  • Mylan to serve as title sponsor of World TeamTennis in three-year agreement

    PITTSBURGH — Generic drug maker Mylan and World TeamTennis announced a three-year agreement under which WTT will be renamed Mylan World TeamTennis.

  • Par to acquire 14 generics

    WOODCLIFF LAKE, N.J. — Par Pharmaceutical Cos. has entered into agreements with Watson Pharmaceuticals and Actavis to purchase five generic products currently marketed in the United States by Watson or Actavis, eight abbreviated new drug applications currently awaiting regulatory approval, and a generic product in late-stage development.

X
This ad will auto-close in 10 seconds